FibroBiologics Files 2024 Second Quarter Report

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials [1][3] - The company has over 150 patents issued and pending, covering various clinical pathways including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer [3] Company Overview - FibroBiologics is based in Houston and represents the next generation of medical advancement in cell therapy [3] - The company has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission [1]